Following a full submission
AWMSG advice |
|||
Status: Recommended | |||
Nitisinone (Orfadin®) is recommended for use within NHS Wales for the treatment of adult patients with alkaptonuria. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
Medicine name | nitisinone (Orfadin®) | ||
Formulation | 10 mg hard capsule | ||
Reference number | 2322 | ||
Indication | Treatment of adult patients with alkaptonuria |
||
Company | Swedish Orphan Biovitrum Ltd | ||
BNF chapter | Nutrition & blood | ||
Submission type | Full | ||
Status | Recommended | ||
Advice number | 1021 | ||
NMG meeting date | 07/07/2021 | ||
AWMSG meeting date | 14/09/2021 | ||
Date of issue | 30/09/2021 | ||
Commercial arrangement | WPAS |